Pharmacopsychiatry 2004; 37(6): 307-308
DOI: 10.1055/s-2004-832692
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Sleepwalking Associated with Reboxetine in a Young Female Patient with Major Depression

A Case ReportH. E. Künzel1 , A. Schuld1 , T. Pollmächer1
  • 1Max Planck Institute of Psychiatry, Munich, Germany
Further Information

Publication History

Received: 12.1.2004 Revised: 27.4.2004

Accepted: 27.4.2004

Publication Date:
19 November 2004 (online)

Several psychotropic compounds are known to influence the sleep-EEG. In very rare cases sleep abnormalities like parasomnia or arousal disorders have additionally been reported during psychotropic drug treatment. We report the case of a 19-year old female patient with a depressive episode and intermittent somnambulism under treatment with reboxetine. The patient with a history of somnambulism in early childhood again suffered from episodes of somnabulism which disappeared after a dose reduction of the drug. In patients having a predisposition for developing parasomnia, a treatment with reboxetine might induce somnambulism.

References

  • 1 Farina B, Della Marca G, Mennuni G, Mazza S, De Risio S, Di Giannantonio M. The effects of reboxetine on human sleep architecture in depression: preliminary results.  J Affect Dis. 2002;  71 273-275
  • 2 Ferrandiz-Santos J A, Mataix-Sanjuan A L. Amitriptyline and somnambulism.  Ann Pharmacother. 2000;  34 1208
  • 3 Kolivakis T T, Margolese H C, Beauclair L. et al . Olanzapine-Induced Somnambulism.  Am J Psychiatry. 2001;  158 1158
  • 4 Kuenzel H E, Murck H, Held K, Ziegenbein M, Steiger A. Reboxetine induces similar sleep EEG changes like SSR’s in patients with depression. Pharmacopsychiatry, in press
  • 5 Ohayon M M, Guilleminault C, Priest R G. Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders.  J Clin Psychiatry. 1999;  60 268-276
  • 6 Schenck C H, Mahowald M W. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults.  Am J Med. 1996;  100 333-337
  • 7 Stahl S M, Mendels J, Schwartz G E. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.  J Clin Psychopharmacology. 2002;  22 388-392
  • 8 van Bemmel A L, Vermeeren M T, Ruigt G. et al . The acute effects of the noradrenaline reuptake inhibitor Org 4428 on EEG sleep in healthy volunteers.  Neuropsychobiology. 1999;  40 107-114

Dr. Thomas Pollmächer

Max Planck Institute of Psychiatry

Kraepelinstraße 10

80804 Munich

Germany

Phone: +49 89 30622 572

Fax: +49 89 30622 562

Email: topo@mpipsykl.mpg.de

    >